FDA might still approve it due to it met first goal and the drug is pretty safe, and there isn't a drug for lupus for a looong time. I am totally out of HGSI, but might buy back later. I am just playing with GNVC, PPG lately.
I don't think the 76-week failure is really that bad. If you look at the results, they're pretty similar to the 52 week results. While having extra-promising 76 week results would have been nice, my understanding is that this study is just extra, and as long as the 52 week results were maintained, there should be little to worry about. i.e., the primary (52) endpoint was successfully obtained and the secondary was not--so the drug, while being good enough, failed to be extra-awesome?
I mean they'd really only have to get unlucky a handful of times (with say flare-ups) to kick that p value up into the range of "statistical insignificance." And it's not a "range" either; it's like if p = 0.04999, you're good. But if p = 0.0500001, you fail.
*shrug* I'm still happy with money in HGSI. Sucks losing 6% today, but what can you do. If I had more cash on hand, I'd probably buy more shares to be honest.